-
公开(公告)号：WO2017064670A3
公开(公告)日：2017-06-01
申请号：PCT/IB2016056180
申请日：2016-10-14
发明人： KHOURY MAROUN , ALCAYAGA FRANCISCA
CPC分类号： A61K31/5383 , A61K31/198 , A61K31/407 , A61K31/4164 , A61K31/43 , A61K31/431 , A61K31/496 , A61K31/546 , A61K31/7056 , A61K35/12 , A61K2300/00
摘要： The present invention offers a solution to the lack of effective alternative treatments to fight infectious disease, preferably involving sepsis, comprising active ingredients obtained by non- intrusive and efficient methods. In particular, the present invention is the first to show that mesenchymal stem cells obtained from menstrual fluids (MenSCs) have the capacity to control infectious diseases, especially those leading to a reaction of the host body like sepsis. As shown herein, in vivo experiments illustrate that MenSCs have antibacterial activity in vitro, increase the survival rates of a mouse model for sepsis, regulate several parameters that are altered in sepsis patients and that are related with multi-organ dysfunction, such as the levels of Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), alkaline phosphatase (ALP), glucose in blood, serum albumin, lung injury. Results show that in the mouse model for sepsis, MenScs also regulate the pro- and anti-inflammatory cytokine levels, reduce the loss of lymphocytes during sepsis and systemic bacterial proliferation in blood. The conditioned medium of MenSCs also increases the survival rates of mouse animals affected by sepsis. Overall, the invention offers a promising alternative method to treat infectious diseases. Since it is principally composed of stem cells present in menstrual fluid, the invention provides an ease access and repeated sampling in a non-invasive manner. Such attributes allow the rapid production of the treatment.
摘要翻译： 本发明提供了一种解决方案，其缺乏有效的替代疗法来对抗感染性疾病，优选涉及脓毒症，其包含通过非侵入性和有效方法获得的活性成分。 具体而言，本发明首次显示从月经液（MenSCs）获得的间充质干细胞具有控制感染性疾病的能力，特别是导致宿主体如脓毒症反应的那些。 如本文所示，体内实验说明MenSC在体外具有抗菌活性，增加小鼠模型对脓毒症的存活率，调节在脓毒症患者中改变的并且与多器官功能障碍相关的若干参数，例如水平 谷丙转氨酶（ALT），天冬氨酸转氨酶（AST），碱性磷酸酶（ALP），血糖，血清白蛋白，肺损伤。 结果显示，在小鼠脓毒症模型中，MenScs还调节促炎和抗炎细胞因子水平，减少败血症期间淋巴细胞的损失和血液中全身性细菌增殖。 MenSC的条件培养基也增加了受败血症影响的小鼠的存活率。 总体而言，本发明提供了治疗感染性疾病的有前途的替代方法。 由于它主要由存在于月经液中的干细胞组成，因此本发明提供了以非侵入方式轻松进入和重复采样。 这些属性使得治疗的快速生产成为可能。
-
2.发明申请
公开(公告)号：WO2017064667A3
公开(公告)日：2017-06-22
申请号：PCT/IB2016056176
申请日：2016-10-14
申请人： UNIV DE LOS ANDES , CELLS FOR CELLS S P A , ACEVEDO JUAN PABLO , WILKENS CAMILA , KHOURY MAROUN , RIVET CHRISTOPHER
IPC分类号： A61F2/00
CPC分类号： B29C41/14 , B29C41/22 , B29K2089/00 , B29L2031/7534
摘要： The present invention overcomes all the above drawbacks and provides a versatile method for the fabrication of multilayer hollow tubes that uses a layer-by-layer rod dipping approach using different biomaterials. The device enables fine control over fabrication parameters, such as ascending/descending speeds, rod rotational velocity, and crosslinking or polymerization time. All these technologies allows the generation of more complex multilayer hollow tubes such as vessel-like structures, urethral grafting, prostate grafting and the like.
摘要翻译： 本发明克服了所有上述缺点，并且提供了一种用于制造多层中空管的通用方法，其使用使用不同生物材料的逐层浸入法。 该装置能够精确控制制造参数，例如上升/下降速度，棒旋转速度以及交联或聚合时间。 所有这些技术允许产生更复杂的多层中空管，例如血管样结构，尿道移植物，前列腺植入物等。
-
搜索结果
2 条记录 (耗时 0.01 秒)
